SOS AMI Selatogrel
|
abstract
|
Multi-center, double-blind, randomized, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of
self-administered subcutaneous selatogrel for prevention of
all-cause death and treatment of acute myocardial infarction in
subjects with a recent history of acute myocardial infarction
|
| |
|
|
type of project
|
clinical studies
|
|
status
|
ongoing - recruiting phase
|
|
start of project
|
2022
|
|
end of project
|
2026
|
|
study design
|
prospective, multi-center, double-blind, randomized,
placebo-controlled, parallel-group, Phase 3 study
|
|
responsible person
|
Prof. Micha Maeder
|
additional links & downloads
